Treatment of Insomnia in Adults
Cognitive behavioral therapy for insomnia (CBT-I) should be the first-line treatment for all adults with chronic insomnia, delivered in-person or digitally, before considering any pharmacological intervention 1, 2.
Non-Pharmacologic Treatment Approach
Primary Treatment: CBT-I
CBT-I is strongly recommended as initial therapy based on high-quality evidence and can be implemented directly in primary care settings 1. This multicomponent intervention includes:
- Cognitive therapy addressing maladaptive beliefs about sleep
- Behavioral interventions including sleep restriction and stimulus control
- Sleep hygiene education
Delivery methods are flexible and equally effective 1:
- Individual or group therapy sessions
- Telephone-based programs
- Web-based/digital modules
- Self-help materials
The 2023 European guideline reinforces this recommendation with the strongest evidence grade, noting CBT-I effectiveness even in patients with medical and psychiatric comorbidities 2. The non-invasive nature means adverse effects are likely mild, though specific harms data remain limited 1.
Adjunctive Non-Pharmacologic Options
Light therapy and exercise interventions may provide additional benefit when combined with CBT-I, though evidence is moderate 2. These should be considered supplementary rather than standalone treatments.
Insufficient or negative evidence exists for: complementary/alternative therapies, acupuncture, homeopathy, and antihistamines 1, 3.
Pharmacologic Treatment Approach
When to Consider Medications
Pharmacotherapy should only be offered when CBT-I is insufficiently effective or unavailable 2, 3. This represents a critical decision point—exhaust behavioral interventions first.
Short-Term Pharmacologic Options (≤4 weeks)
For initial pharmacologic management, the following have strong evidence for short-term use:
- Benzodiazepine receptor agonists (Z-drugs): Effective but carry risks of cognitive impairment, falls, and motor vehicle accidents 1, 2
- Benzodiazepines: Effective short-term but associated with serious adverse effects including dementia and fractures in observational studies 1
- Low-dose sedating antidepressants: Moderate evidence for short-term efficacy 2
- Daridorexant (orexin receptor antagonist): Strong evidence for use up to 3 months or longer 2
Longer-Term Pharmacologic Options
Dual orexin receptor antagonists (DORAs) can be used for periods extending beyond 3 months with strong evidence 2. These represent the most favorable risk-benefit profile for extended use among pharmacologic agents.
Prolonged-release melatonin may be used for up to 3 months specifically in patients ≥55 years old 2.
Important Caveats and Pitfalls
The FDA specifically warns about:
- Lower doses required for women, older adults, and debilitated patients with benzodiazepines and Z-drugs 1
- Cognitive and behavioral changes including driving impairment
- Recommendation for short-term use only, though many patients continue long-term 1
Avoid these medications due to insufficient evidence or unfavorable risk profiles:
- Antihistaminergic drugs (strong recommendation against) 2
- Antipsychotics 2
- Fast-release melatonin 2
- Ramelteon 2
- Phytotherapeutics/herbal remedies 2, 3
Clinical Algorithm for Pharmacologic Selection
When CBT-I fails or is unavailable:
- First consideration: Orexin receptor antagonists (daridorexant) for favorable long-term safety profile 2
- Alternative short-term options (≤4 weeks): Benzodiazepine receptor agonists or low-dose sedating antidepressants, with careful attention to FDA dosing recommendations 1, 2
- For patients ≥55 years: Consider prolonged-release melatonin for up to 3 months 2
- If longer treatment needed: Reassess benefits versus risks; orexin antagonists have best evidence for extended use 2
Critical consideration: Evidence for comparative effectiveness between different pharmacologic agents remains insufficient 1, but newer orexin antagonists demonstrate more favorable long-term safety data compared to traditional benzodiazepines and Z-drugs.